188 related articles for article (PubMed ID: 17326263)
1. The follow-up management of non-metastatic renal cell carcinoma: definition of a surveillance protocol.
Antonelli A; Cozzoli A; Zani D; Zanotelli T; Nicolai M; Cunico SC; Simeone C
BJU Int; 2007 Feb; 99(2):296-300. PubMed ID: 17326263
[TBL] [Abstract][Full Text] [Related]
2. Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system.
Lam JS; Shvarts O; Leppert JT; Pantuck AJ; Figlin RA; Belldegrun AS
J Urol; 2005 Aug; 174(2):466-72; discussion 472; quiz 801. PubMed ID: 16006866
[TBL] [Abstract][Full Text] [Related]
3. Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy: a multicenter European study.
Cindolo L; Patard JJ; Chiodini P; Schips L; Ficarra V; Tostain J; de La Taille A; Altieri V; Lobel B; Zigeuner RE; Artibani W; Guillé F; Abbou CC; Salzano L; Gallo C
Cancer; 2005 Oct; 104(7):1362-71. PubMed ID: 16116599
[TBL] [Abstract][Full Text] [Related]
4. Integrated staging systems for conventional renal cell carcinoma: a comparison of two prognostic models.
Martella O; Galatioto GP; Necozione S; Pomante R; Vicentini C
Arch Ital Urol Androl; 2011 Sep; 83(3):121-7. PubMed ID: 22184835
[TBL] [Abstract][Full Text] [Related]
5. Use of the University of California Los Angeles Integrated Staging System (UISS) to predict survival in localized renal cell carcinoma in an Asian population.
Ng CF; Wan SH; Wong A; Lai FM; Hui P; Cheng CW
Int Urol Nephrol; 2007; 39(3):699-703. PubMed ID: 17180738
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of nephron-sparing surgery for renal cell carcinoma: analysis based on the new 1997 tumor-node-metastasis staging system.
Belldegrun A; Tsui KH; deKernion JB; Smith RB
J Clin Oncol; 1999 Sep; 17(9):2868-75. PubMed ID: 10561364
[TBL] [Abstract][Full Text] [Related]
7. Renal cell carcinoma: The role of radical surgery on different patterns of local or distant recurrence.
Di Franco G; Palmeri M; Sbrana A; Gianardi D; Furbetta N; Guadagni S; Bianchini M; Stefanini G; Adamo G; Pollina LE; Galli L; Di Candio G; Morelli L
Surg Oncol; 2020 Dec; 35():106-113. PubMed ID: 32866943
[TBL] [Abstract][Full Text] [Related]
8. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study.
Patard JJ; Kim HL; Lam JS; Dorey FJ; Pantuck AJ; Zisman A; Ficarra V; Han KR; Cindolo L; De La Taille A; Tostain J; Artibani W; Dinney CP; Wood CG; Swanson DA; Abbou CC; Lobel B; Mulders PF; Chopin DK; Figlin RA; Belldegrun AS
J Clin Oncol; 2004 Aug; 22(16):3316-22. PubMed ID: 15310775
[TBL] [Abstract][Full Text] [Related]
9. Impact of routine imaging in the diagnosis of recurrence for patients with localized and locally advanced renal tumor treated with nephrectomy.
Gires B; Khene ZE; Bigot P; Alimi Q; Peyronnet B; Verhoest G; Manunta A; Bensalah K; Mathieu R
World J Urol; 2019 Dec; 37(12):2727-2736. PubMed ID: 30895362
[TBL] [Abstract][Full Text] [Related]
10. Positive surgical margin following radical nephrectomy is an independent predictor of local recurrence and disease-specific survival.
Abu-Ghanem Y; Ramon J; Berger R; Kaver I; Fridman E; Leibowitz-Amit R; Dotan ZA
World J Surg Oncol; 2017 Nov; 15(1):193. PubMed ID: 29096642
[TBL] [Abstract][Full Text] [Related]
11. Local and Regional Recurrences of Clinically Localized Renal Cell Carcinoma after Nephrectomy: A 15 Year Institutional Experience with Prognostic Features and Oncologic Outcomes.
Ray S; Cheaib JG; Biles MJ; Pineault KG; Johnson MH; Ged YMA; Markowski MC; Singla N; Allaf ME; Pierorazio PM
Urology; 2021 Aug; 154():201-207. PubMed ID: 33864855
[TBL] [Abstract][Full Text] [Related]
12. The 'Stage, Size, Grade and Necrosis' score is more accurate than the University of California Los Angeles Integrated Staging System for predicting cancer-specific survival in patients with clear cell renal cell carcinoma.
Ficarra V; Novara G; Galfano A; Brunelli M; Cavalleri S; Martignoni G; Artibani W
BJU Int; 2009 Jan; 103(2):165-70. PubMed ID: 18782313
[TBL] [Abstract][Full Text] [Related]
13. Pathological and genetic markers improve recurrence prognostication with the University of California Los Angeles Integrated Staging System for patients with clear cell renal cell carcinoma.
Kroeger N; Lebacle C; Hein J; Rao PN; Nejati R; Wei S; Burchardt M; Drakaki A; Strother M; Kutikov A; Uzzo R; Pantuck AJ
Eur J Cancer; 2022 Jun; 168():68-76. PubMed ID: 35461012
[TBL] [Abstract][Full Text] [Related]
14. Matched comparison of radical nephrectomy vs nephron-sparing surgery in patients with unilateral renal cell carcinoma and a normal contralateral kidney.
Lau WK; Blute ML; Weaver AL; Torres VE; Zincke H
Mayo Clin Proc; 2000 Dec; 75(12):1236-42. PubMed ID: 11126830
[TBL] [Abstract][Full Text] [Related]
15. Renal fossa recurrence after radical nephrectomy: Current management, and oncological outcomes.
Romeo A; Garcia Marchiñena P; Jurado AM; Gueglio G
Urol Oncol; 2020 Feb; 38(2):42.e7-42.e12. PubMed ID: 31711833
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathologic and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma.
Lam JS; Shvarts O; Said JW; Pantuck AJ; Seligson DB; Aldridge ME; Bui MH; Liu X; Horvath S; Figlin RA; Belldegrun AS
Cancer; 2005 Jun; 103(12):2517-25. PubMed ID: 15880379
[TBL] [Abstract][Full Text] [Related]
17. Partial Nephrectomy is Associated with Higher Risk of Relapse Compared with Radical Nephrectomy for Clinical Stage T1 Renal Cell Carcinoma Pathologically Up Staged to T3a.
Shah PH; Moreira DM; Patel VR; Gaunay G; George AK; Alom M; Kozel Z; Yaskiv O; Hall SJ; Schwartz MJ; Vira MA; Richstone L; Kavoussi LR
J Urol; 2017 Aug; 198(2):289-296. PubMed ID: 28274620
[TBL] [Abstract][Full Text] [Related]
18. Positive Surgical Margins Predict Progression-free Survival After Nephron-sparing Surgery for Renal Cell Carcinoma: Results From a Single Center Cohort of 459 Cases With a Minimum Follow-up of 5 Years.
Tellini R; Antonelli A; Tardanico R; Fisogni S; Veccia A; Furlan MC; Carobbio F; Cozzoli A; Zanotelli T; Simeone C
Clin Genitourin Cancer; 2019 Feb; 17(1):e26-e31. PubMed ID: 30266249
[TBL] [Abstract][Full Text] [Related]
19. Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN Project).
Brookman-May S; May M; Shariat SF; Xylinas E; Stief C; Zigeuner R; Chromecki T; Burger M; Wieland WF; Cindolo L; Schips L; De Cobelli O; Rocco B; De Nunzio C; Feciche B; Truss M; Gilfrich C; Pahernik S; Hohenfellner M; Zastrow S; Wirth MP; Novara G; Carini M; Minervini A; Simeone C; Antonelli A; Mirone V; Longo N; Simonato A; Carmignani G; Ficarra V;
Eur Urol; 2013 Sep; 64(3):472-7. PubMed ID: 22748912
[TBL] [Abstract][Full Text] [Related]
20. Long-term oncologic outcomes after radiofrequency ablation for T1 renal cell carcinoma.
Psutka SP; Feldman AS; McDougal WS; McGovern FJ; Mueller P; Gervais DA
Eur Urol; 2013 Mar; 63(3):486-92. PubMed ID: 22959191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
